Product Images Rivastigmine

Not available.*

This appears to be a chart showing the levels of Rivastigmine, measured in ng/mL, at different dosages and sample sizes. Three different dosages are listed, with 19, 22, and 22 samples respectively. The levels of Rivastigmine were measured at 20, 16, and 12 ng/mL, but it's not clear which dosage corresponds to which level.*

The text is describing the change in ADAS-Cog rating from baseline and clinical improvement during treatment. It also mentions varying amounts and types of medication (capsules and placebo) given.*

This is a description of a clinical trial for Rivastigmine Transdermal System, in which patients improve with the 13.3 mg/24 hr dosage compared to the 9.5mg/24 hr dosage. There is a graph that shows improvement over the weeks of treatment.*

This is a chart depicting the clinical improvement of patients undergoing treatment with Rivastigmine Transdermal System. The chart shows a decline in patients' conditions over a certain number of weeks of treatment. The chart compares the effectiveness of two doses - the 13.3 mg/24 hr dose and the 9.5 mg/24 hr dose - where the higher dose shows statistically significant improvement over the lower dose.*

This appears to be a clinical study with data on LS (least squares) mean differences and improvements in patients with a certain medical condition, possibly related to treatment. The text also includes data on LS mean change and standard errors for two different treatments over the course of several weeks. The statistical significance of the data is also mentioned. However, without more context or information, it is difficult to provide a more specific description or interpretation of the results.*

This text provides statistical data on clinical improvement and decline of patients who underwent a 16-week treatment involving Rivasligmine Transdermal System at 13.3 mg/24 hr and 4.6 mg/24 hr doses. The results include LS mean diff., standard errors, p-values, and statistical significance levels, presented in a table format. The data is obtained through an analysis of covariance model that has been adjusted for pooled center and baseline.*

This is a description of a medication called Rivastigmine that comes in the form of a transdermal system. The medication is only for transdermal use on the body. The package contains one system and includes protective liners and an adhesive with the medicine. There is a reference to Zydus, which may be the manufacturer of the medication.*

This appears to be a form or questionnaire for a medical examination, with options for indicating the location of pain or discomfort on the body. The options listed include the left or right upper arm, left or right side of the chest, left or right upper back, and left or right lower back. The form also includes diagrams of the front and back of the body, with a selection box for indicating the location of the issue in those areas. There is not enough information provided to determine the purpose of the medical examination or the context in which this form is being used.*

The text contains only a heading "Protective Liners" and a partial sentence "Sticky surface of transdermal system". No further information is available to provide a useful description.*

This text appears to be instructions for disposing of a slide folded patch. It advises placing the patch in the trash and folding the sticky sides together into an empty pouch. The instructions also caution to keep the patch away from children and pets.*

This is a medication package for Rivastigmine, a drug used in the treatment of Alzheimer's disease. The medication comes in the form of a transdermal system that should be used only through the skin. The package contains 30 systems with each system delivering an unknown amount of medication. The NDC number is 7071011967.*

This is a description of a medication called Rivastigmine Transdermal System. It comes in the form of a patch that is applied to the skin, and each patch contains a certain amount of the medication. The package contains 30 of these patches, which can only be used for transdermal (through the skin) administration.*

This appears to be a pharmaceutical label for a medication called Rivastigmine, delivered through a transdermal patch system. The label includes information about the National Drug Code, dosage and application instructions, and manufacturer information.*